Melanie Saint-Jean
Overview
Explore the profile of Melanie Saint-Jean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zenatri M, Collins M, Alberto T, Farina A, Collardeau-Frachon S, Saint-Jean M, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):45.
PMID: 39751892
Immune checkpoint inhibitors (ICI), i.e., anti-PD1/PDL1 and anti-CTLA-4, have reshaped the prognosis of many cancers. Increased use of ICI has led to the onset of new adverse events. Neurological immune-related...
2.
Tzoumpa S, Villette B, Granel-Brocard F, Dutriaux C, Memmi A, Jeudy G, et al.
Immunotherapy
. 2024 Sep;
16(16-17):1029-1037.
PMID: 39268924
Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for...
3.
Rousset P, Nardin C, Maubec E, Heidelberger V, Picard A, Troin L, et al.
Oncologist
. 2024 Jul;
29(10):e1364-e1372.
PMID: 38956747
Background: Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in...
4.
Amini-Adle M, Arnault J, Aubin F, Beneton N, Bens G, Brunet-Possenti F, et al.
Ann Dermatol Venereol
. 2024 Feb;
151(1):103243.
PMID: 38325268
No abstract available.
5.
Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, et al.
J Neurol
. 2023 Dec;
271(3):1473-1482.
PMID: 38052771
No abstract available.
6.
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509227
Background: The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the...
7.
Lhuillier M, Briere M, Artifoni M, Chapal M, Peuvrel L, Saint-Jean M
Immunotherapy
. 2023 Feb;
15(4):229-234.
PMID: 36789558
Cemiplimab, a human monoclonal antibody directed against PD-1, has provided more options in the treatment of locally advanced or metastatic cutaneous squamous-cell carcinoma at an unresectable state. Immune checkpoint inhibitors...
8.
Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Quereux G, et al.
Medicine (Baltimore)
. 2020 Jul;
99(29):e21329.
PMID: 32702928
In BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a...
9.
Bocquet-Tremoureux S, Scharbarg E, Nguyen J, Varey E, Quereux G, Saint-Jean M, et al.
Eur J Dermatol
. 2019 Aug;
29(3):315-321.
PMID: 31389790
Background: Anti-PD1 antibodies have revolutionized the management of patients with advanced melanoma. In clinical trials, the efficacy of nivolumab is being tested in selected populations of patients. Objectives: The aim...
10.
Saint-Jean M, Corvec S, Nguyen J, Le Moigne M, Boisrobert A, Khammari A, et al.
J Am Acad Dermatol
. 2019 Mar;
81(3):851-852.
PMID: 30905801
No abstract available.